Clindamycin Phosphate
drug drugOn this page
Also known as CleocinCleocin phosphateCleocin tClinadacClinda-dermClindacClindagelClindamycin phosphate component of duacClindamycin phosphate component of zianaClindamycin phosphate hydrateClindamycin phosphate system suitabilityClindesseClindetsDalacinDalacin c phosDalacin pDalacin tEvoclinNSC-618653
Summary
Clindamycin Phosphate (CHEMBL3184512) is an approved small molecule; indicated across 21 conditions including pneumonia and endometritis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 21 conditions
- Clinical trials: 7
- Chemistry: 505 Da · C18H34ClN2O8PS
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3184512 |
| Name | Clindamycin Phosphate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 443385 |
| Molecular formula | C18H34ClN2O8PS |
| Molecular weight | 505 |
| InChIKey | UFUVLHLTWXBHGZ-MGZQPHGTSA-N |
SMILES: CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)OP(=O)(O)O)O)O)[C@H](C)Cl
IUPAC name: [(2R,3R,4S,5R,6R)-6-[(1S,2S)-2-chloro-1-[[(2S,4R)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate
Also known as: Cleocin, Cleocin phosphate, Cleocin t, Clinadac, Clinda-derm, Clindac, Clindagel, Clindamycin phosphate, Clindamycin phosphate component of duac, Clindamycin phosphate component of ziana, Clindamycin phosphate hydrate, Clindamycin phosphate system suitability
Patent coverage: 1,760 distinct patent families (5,809 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
14 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| pneumonia | 4 | MONDO:0005249 | EFO:0003106 |
| endometritis | 4 | MONDO:0000918 | EFO:1001312 |
| empyema | 4 | MONDO:0005242 | EFO:0003097 |
| parametritis | 4 | MONDO:0006887 | EFO:1001084 |
| lung abscess | 4 | MONDO:0000744 | EFO:1001362 |
| osteomyelitis | 4 | MONDO:0005246 | EFO:0003102 |
| abscess | 4 | MONDO:0005227 | EFO:0003030 |
| acne | 4 | MONDO:0011438 | EFO:0003894 |
| bacterial vaginosis | 4 | MONDO:0005316 | EFO:0003932 |
| infectious peritonitis | 4 | MONDO:0004522 | EFO:0008588 |
| female reproductive system disorder | 4 | MONDO:0002263 | EFO:0009549 |
| irritable bowel syndrome | 4 | MONDO:0005052 | EFO:0000555 |
| Clostridium difficile colitis | 4 | MONDO:0000705 | EFO:1001314 |
| respiratory tract infectious disorder | 4 | MONDO:0024355 | MONDO:0024355 |
3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| vulvovaginitis | 3 | MONDO:0007019 | EFO:1001240 |
| vaginitis | 3 | MONDO:0002234 | MONDO:0002234 |
| rosacea | 2 | MONDO:0006604 | EFO:1000760 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 7.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| Not specified | 2 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00616330 | PHASE3 | COMPLETED | Vaginal Infection Study |
| NCT00694928 | PHASE3 | COMPLETED | Vaginal Infection Study 2 |
| NCT04469075 | PHASE2 | ACTIVE_NOT_RECRUITING | Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields |
| NCT00361322 | PHASE1/PHASE2 | COMPLETED | Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris |
| NCT04321070 | PHASE1 | COMPLETED | Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris |
| NCT02348463 | Not specified | COMPLETED | Treatment of Bacterial Vaginosis in Early Pregnancy in Skaraborg and the Effect on Spontaneous Preterm Delivery |
| NCT07247851 | Not specified | COMPLETED | Title of the Protocol: Combined Use of Vaginal Clindamycin Cream and Oral Metronidazole Versus Oral Metronidazole |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: pneumonia, endometritis, empyema, parametritis, lung abscess, osteomyelitis, abscess, acne, bacterial vaginosis, infectious peritonitis, female reproductive system disorder, irritable bowel syndrome, Clostridium difficile colitis, respiratory tract infectious disorder
- In clinical trials for: vulvovaginitis, vaginitis, rosacea